Clinical Trial

Adjuvant Oxaliplatin Plus S-1 Versus Docetaxel Plus S-1 for Stage III Gastric Cancer

Name: Adjuvant Oxaliplatin Plus S-1 Versus Docetaxel Plus S-1 for Stage III Gastric Cancer — clinical trial record (NCT07366528)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 3

View on ClinicalTrials.gov →

Summary

This is a multicenter, open-label, phase 3, randomized, non-inferiority study aimed to investigate the effect on disease-free survival of adjuvant chemotherapy with oxaliplatin plus S-1 compared with adjuvant chemotherapy with docetaxel plus S-1 after D2 gastrectomy in patients with stage III gastric cancer.

Trial Details

NCT Number	NCT07366528
Lead Sponsor	Ruijin Hospital
Conditions	Gastric Cancer (GC), Adjuvant Chemotherapy, Stage 3 Cancer, Docetaxel, Oxaliplatin
Enrollment	387 participants
Start Date	2025-12-15
Primary Completion	2028-10-30 (estimated)
Study Completion	2030-10-31 (estimated)
Updated on ClinicalTrials.gov	2026-01-26